株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

降圧薬の世界市場予測:2019-2028年

Global Antihypertensive Drugs Market Forecast 2019-2028

発行 Inkwood Research 商品コード 943442
出版日 ページ情報 英文 188 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
降圧薬の世界市場予測:2019-2028年 Global Antihypertensive Drugs Market Forecast 2019-2028
出版日: 2020年06月21日 ページ情報: 英文 188 Pages
概要

2019年から2028年までの予測期間中、 世界の降圧薬市場は3.21%のCAGRで成長すると推定されています。高血圧の有病率の急増、および高血圧に関連する合併症の認識の高まり、ならびに老年人口および座りがちな生活様式の増加は、市場の成長を牽引する主要な要因となっています。しかし近年の特許の期限切れは、降圧薬市場の成長を妨げると予想されます。安価なジェネリックの市場への参入につながり、市場の拡大を制限すると見込まれます。

当レポートでは、降圧薬の世界市場について調査し、市場の概要、市場成長への主な影響要因の分析、各セグメント・地域別の分析と予測、および主要企業のプロファイルなどを提供しています。

第1章 調査範囲と調査手法

  • 調査目的
  • 調査範囲
  • 調査手法
  • 前提と制限

第2章 エグゼクティブサマリー

  • 市場規模・推計
  • 市場概要

第3章 市場力学

  • 市場定義
  • 主な促進要因
    • 世界的に高血圧の有病率が上昇
    • 可処分所得とヘルスケア支出の急増
    • 高齢者人口の増加
  • 主な抑制要因
    • 特許の有効期限切れ
    • 製品発売の遅延

第4章 主な分析

  • ポーターのファイブフォース分析
  • 規制の枠組み
  • 市場機会マトリックス
  • ベンダー情勢
  • 主な投資の考察

第5章 市場:薬剤クラス別

  • カルシウムチャネル遮断薬
  • ACE阻害薬
  • ベータアドレナリン遮断薬
  • 利尿薬
  • 血管拡張薬
  • その他の薬剤クラス

第6章 市場:エンドユーザー別

  • 病院薬局
  • 小売り薬局
  • Eコマースのウェブサイト・オンラインドラッグストア

第7章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • ロシア
    • ベルギー
    • ポーランド
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • タイ
    • インドネシア
    • ベトナム
    • その他アジア太平洋地域
  • その他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第8章 企業プロファイル

  • ALLERGAN PLC
  • ASPIRE BARIATRICS INC
  • ASTRAZENECA PLC
  • BIO-RAD LABORATORIES INC
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • 第一三共
  • HILL-ROM HOLDINGS INC
  • JOHNSON & JOHNSON
  • LUPIN LIMITED
  • MEDTRONIC PLC
  • MERCK & CO INC
  • NOVARTIS AG
  • PFIZER INC
  • SANOFI
  • SUN PHARMACEUTICAL INDUSTRIES LTD. (RANBAXY LABORATORIES)
図表

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ANTIHYPERTENSIVE DRUGS
  • TABLE 2: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL CALCIUM CHANNEL BLOCKERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL CALCIUM CHANNEL BLOCKERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL ACE INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL ACE INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL BETA-ADRENERGIC BLOCKERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL BETA-ADRENERGIC BLOCKERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL DIURETICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL DIURETICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL VASODILATORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL VASODILATORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL OTHER DRUG CLASS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL OTHER DRUG CLASS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL RETAIL PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL RETAIL PHARMACY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL E-COMMERCE WEBSITES & ONLINE DRUG STORES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL E-COMMERCE WEBSITES & ONLINE DRUG STORES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 26: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 28: EUROPE ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: EUROPE ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 30: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 32: REST OF WORLD ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: REST OF WORLD ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: NUMBER OF AGING POPULATION BY REGION 2017& 2050 (IN MILLION)
  • FIGURE 2: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: VENDOR LANDSCAPE
  • FIGURE 5: KEY INVESTMENT INSIGHTS
  • FIGURE 6: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, IN 2019
  • FIGURE 7: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY CALCIUM CHANNEL BLOCKERS, 2019-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY ACE INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY BETA-ADRENERGIC BLOCKERS, 2019-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DIURETICS, 2019-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY VASODILATORS, 2019-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY OTHER DRUG CLASS, 2019-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, IN 2019
  • FIGURE 14: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY HOSPITAL PHARMACY, 2019-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY RETAIL PHARMACY, 2019-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY E-COMMERCE WEBSITES & ONLINE DRUG STORES, 2019-2028 (IN $ MILLION)
  • FIGURE 17: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 18: THE UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 19: CANADA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 20: EUROPE ANTIHYPERTENSIVE DRUGS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 21: THE UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 22: FRANCE ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 23: GERMANY ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 24: ITALY ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 25: RUSSIA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 26: BELGIUM ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 27: POLAND ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 28: REST OF EUROPE ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 29: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 30: CHINA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 31: JAPAN ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 32: INDIA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 33: AUSTRALIA & NEW ZEALAND ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 34: SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 35: THAILAND ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 36: INDONESIA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 37: VIETNAM ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 38: REST OF ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 39: REST OF WORLD ANTIHYPERTENSIVE DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 40: LATIN AMERICA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 41: MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
目次
Product Code: 32285

KEY FINDINGS

During the forecast period from 2019 to 2028, the global antihypertensive drugs market is estimated to grow with a CAGR of 3.21%. A surge in the prevalence of hypertension and a rise in awareness of complications related to hypertension, as well as an increase in the geriatric population and sedentary lifestyle, are primary factors that drive the market growth.

MARKET INSIGHTS

The growth of the global antihypertensive drugs market is propelled by a worldwide surge in the prevalence of hypertension. Antihypertensive drugs are used to treat patients suffering from hypertension, a medical condition that involves a rise in blood pressure in the arteries. Moreover, an individual who suffers from hypertension is very susceptible to other complications like aneurysm and heart failure. Thus, hypertension requires early diagnosis as well as management by using antihypertensive drugs. The frequency of cardiovascular diseases among the geriatric population is predicted to increase at an alarming rate. Therefore, a steady and rapid rise in the geriatric population is among the key drivers of the antihypertensive drugs market as the aging population is highly vulnerable to high blood pressure. This would further be beneficial for the global antihypertensive drugs market growth as aged individuals continue to become prone to hypertension and other cardiovascular complications. Conversely, an upsurge in research related to antihypertensive drugs in developing economies, would offer profitable prospects through the forecast period. However, recent patent expirations are expected to hinder the growth of the antihypertensive drugs market. They lead to the entrance of cheap generics in the market and thus limit market expansion. For instance, Bystolic, an antihypertensive drug by Allergan, will lose patent protection in 2021.

REGIONAL INSIGHTS

The geographical segmentation of the global antihypertensive drugs market includes Asia Pacific, Europe, North America, and the rest of the world. According to Inkwood Research, North America dominated the antihypertensive drugs market in 2019, possessing a revenue share of 35.02%. It is anticipated that the region will continue this trend throughout the forecast period, as a result of a rise in the prevalence of hypertension and chronic kidney disorders. Additionally, the presence of major companies like Johnson & Johnson propels the antihypertensive drugs market growth in the North America region.

COMPETITIVE INSIGHTS

An intense rivalry exists among the major enterprises in the market, and the degree of competition is extensive. Allergan PLC, Aspire Bariatrics Inc, Bio-Rad Laboratories Inc, Johnson & Johnson, Sanofi, etc. are among the renowned companies in the market.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING PREVALENCE OF HYPERTENSION ACROSS THE GLOBE
    • 3.2.2. SURGE IN DISPOSABLE INCOME AND HEALTHCARE SPENDING
    • 3.2.3. RISING AGING POPULATION
  • 3.3. KEY RESTRAINTS
    • 3.3.1. PATENT EXPIRATIONS
    • 3.3.2. DELAY IN PRODUCT LAUNCHES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. REGULATORY FRAMEWORK
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY DRUG CLASS

  • 5.1. CALCIUM CHANNEL BLOCKERS
  • 5.2. ACE INHIBITORS
  • 5.3. BETA-ADRENERGIC BLOCKERS
  • 5.4. DIURETICS
  • 5.5. VASODILATORS
  • 5.6. OTHER DRUG CLASS

6. MARKET BY END-USER

  • 6.1. HOSPITAL PHARMACY
  • 6.2. RETAIL PHARMACY
  • 6.3. E-COMMERCE WEBSITES & ONLINE DRUG STORES

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. THE UNITED KINGDOM
    • 7.2.2. FRANCE
    • 7.2.3. GERMANY
    • 7.2.4. ITALY
    • 7.2.5. RUSSIA
    • 7.2.6. BELGIUM
    • 7.2.7. POLAND
    • 7.2.8. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. JAPAN
    • 7.3.3. INDIA
    • 7.3.4. AUSTRALIA & NEW ZEALAND
    • 7.3.5. SOUTH KOREA
    • 7.3.6. THAILAND
    • 7.3.7. INDONESIA
    • 7.3.8. VIETNAM
    • 7.3.9. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST & AFRICA

8. COMPANY PROFILES

  • 8.1. ALLERGAN PLC
  • 8.2. ASPIRE BARIATRICS INC
  • 8.3. ASTRAZENECA PLC
  • 8.4. BIO-RAD LABORATORIES INC
  • 8.5. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • 8.6. DAIICHI SANKYO COMPANY LIMITED
  • 8.7. HILL-ROM HOLDINGS INC
  • 8.8. JOHNSON & JOHNSON
  • 8.9. LUPIN LIMITED
  • 8.10. MEDTRONIC PLC
  • 8.11. MERCK & CO INC
  • 8.12. NOVARTIS AG
  • 8.13. PFIZER INC
  • 8.14. SANOFI
  • 8.15. SUN PHARMACEUTICAL INDUSTRIES LTD. (RANBAXY LABORATORIES)